A method of administering an antitumor compound

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4162 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2668363

The present invention provides a method of treating a mammal, including humans, suffering from tumour, comprising administering Compound 1 of the formula A or a pharmaceutically acceptable salt thereof, to said mammal by intravenous infusion, characterised in that Compound 1 is conveniently administered employing particular schedules, infusion times and doses which allow a more efficacious treatment. Compound 1 of formula A is an aurora inhibitor, chemical name N-{5-[(2R)-2-methoxy- 2-phenylethanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazol-3-yl}-4-(4-methylpiperazin-1-yl) benzamide, and the method is preferably for the treatment of patients having solid tumours or hematopoietic malignant tumours. The use of Compound 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for the treatment of tumours employing particular schedules, infusion times and doses, as well as the use of Compound 1 for treatment of tumours in the same manner are also provided.

La présente invention concerne un procédé de traitement d'une tumeur chez le mammifère, y compris de l'être humain. Ledit procédé comporte l'administration d'un Composé 1 représenté par la formule A ou d'un sel pharmaceutiquement acceptable de celui-ci audit mammifère par infusion intraveineuse caractérisée en ce que le Composé 1 est administré de façon très commode selon un horaire, un temps d'infusion et de doses spécifiques qui permettent un traitement plus efficace. Le Composé 1 représenté par la formula A est un inhibiteur d'aurora, nom chimique N-{5-[(2R)-2-méthoxy-2-phényléthanoyl]-1,4,5,6-tétrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl) benzamide ; le procédé couvre, de préférence, le traitement de patients présentant des tumeurs solides ou des tumeurs malignes hématopoïétiques. L'invention concerne également l'utilisation du Composé 1, ou d'un sel pharmaceutiquement acceptable de celui-ci, et d'un support ou excipient pharmaceutiquement acceptable, dans la fabrication d'un médicament pour le traitement de tumeurs selon un horaire, un temps d'infusion et de doses spécifiques ainsi que l'utilisation du Composé 1 pour un traitement de tumeurs semblable.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

A method of administering an antitumor compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A method of administering an antitumor compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A method of administering an antitumor compound will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1530650

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.